Physician profile
George E Castro
NPI 1093721334
$2,161.85
in general payments reported to CMS, 2019-2025
23 companies · $43.86 in 2025
The $43.86 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $471 · 2021: $655 · 2022: $280 · 2023: $89.78 · 2024: $144 · 2025: $43.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $277.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $344.44 | 2019-2023 | Xarelto |
| Pfizer INC. | $343.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $190.20 | 2020-2021 | |
| Octapharma USA, INC. | $144.29 | 2024 | Octagam Immune Globulin (Human) |
| Novartis Pharmaceuticals Corporation | $135.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $119.57 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $116.91 | 2019-2023 | |
| Atricure, INC. | $110.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.23 | 2021-2022 | |
| Abbott Laboratories | $101.03 | 2021-2022 | |
| Daiichi Sankyo INC. | $65.99 | 2020-2022 | |
| Biotronik INC. | $49.93 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.22 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $45.07 | 2022-2023 | |
| Esperion Therapeutics, INC. | $44.75 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $39.77 | 2019 | |
| Boston Scientific Corporation | $39.28 | 2019-2025 | Bodyguardian |
| Medicomp INC | $29.37 | 2021 | |
| Edwards Lifesciences Corporation | $27.32 | 2021 | |
| Getinge USA Sales, LLC | $18.97 | 2025 | Cardiosave Rescue |
| Amgen INC. | $17.22 | 2019 | |
| Cvrx, INC. | $14.61 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.